<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-1-98-104</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1107</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>Тромбоэмболические осложнения при антифосфолипидном синдроме и анкилозирующем спондилите (два клинических случая)</article-title><trans-title-group xml:lang="en"><trans-title>Thromboembolic complications in antiphospholipid syndrome and ankylosing spondylitis (two clinical cases)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6685-7670</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нурбаева</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nurbaeva</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, 115522, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5217-4932</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чельдиева</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheldieva</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</p><p>Москва, 115522, Каширское шоссе, 34А,</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Department of Rheumatology, Russian Medical Academy of Continuing Professional Education</p><p>34A, Kashirskoe Shosse, Moscow 115522,</p><p>2/1, Barrikadnaya St., Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1318-1894</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шумилова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shumilova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, 115522, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</p><p>Москва, 115522, Каширское шоссе, 34А,</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Department of Rheumatology, Russian Medical Academy of Continuing Professional Education</p><p>34A, Kashirskoe Shosse, Moscow 115522,</p><p>2/1, Barrikadnaya St., Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3552-2522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетняк</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnyak</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Магомедалиевна Решетняк</p><p>Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</p><p>Москва, 115522, Каширское шоссе, 34А,</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Tatiana Magomedalievna Reshetnyak</p><p>Department of Rheumatology, Russian Medical Academy of Continuing Professional Education</p><p>34A, Kashirskoe Shosse, Moscow 115522,</p><p>2/1, Barrikadnaya St., Build. 1, Moscow 125993</p></bio><email xlink:type="simple">t_reshetnyak@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2021</year></pub-date><volume>15</volume><issue>1</issue><fpage>98</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нурбаева К.С., Чельдиева Ф.А., Шумилова А.А., Лила А.М., Решетняк Т.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Нурбаева К.С., Чельдиева Ф.А., Шумилова А.А., Лила А.М., Решетняк Т.М.</copyright-holder><copyright-holder xml:lang="en">Nurbaeva K.S., Cheldieva F.A., Shumilova A.A., Lila A.M., Reshetnyak T.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1107">https://mrj.ima-press.net/mrj/article/view/1107</self-uri><abstract><p>Представлены два пациента с клиническими проявлениями антифосфолипидного синдрома (АФС) и анкилозирующего спондилита (АС). Особенностью этих случаев являются дебют заболеваний в детском возрасте, а также наличие не только внескелетных проявлений, но и осложнений или проявлений другой патологии. В первом случае – это тромбоз поверхностных вен голеней с развитием посттромбофлебитического синдрома, во втором – порок аортального клапана как следствие перенесенного аортита с дилатацией восходящего отдела аорты, что привело к протезированию аортального клапана и последующей его дисфункции в результате тромбоза протеза клапана. Обсуждается частота выявления антифосфолипидных антител (аФЛ), АФС и тромбозов при АС. Отдельно рассмотрена роль ингибиторов фактора некроза опухоли α (иФНОα) в индукции синтеза аФЛ и развитии АФС у пациентов с АС. Данные о встречаемости аФЛ, причинах развития тромбозов при АФС и роли иФНОα остаются неполными. Возможно, сочетание АФС и АС – недооцененная проблема, а имеющиеся в литературе сведения не отражают реальных цифр. Очевидно, что необходимы дальнейшие исследования в этом направлении для улучшения курации больных АС с тромбозами.</p></abstract><trans-abstract xml:lang="en"><p>We presented two clinical cases with clinical manifestations of antiphospholipid syndrome (APS) and ankylosing spondylitis (AS). The peculiarity of these cases is the onset of diseases in childhood, as well as the presence of not only extra-skeletal manifestations, but also complications or manifestations of other pathology. In the first case, it was thrombosis of the superficial veins of the lower limbs with the development of postthrombotic syndrome. In the second case, aortic valve defect, as a result of aortitis with a dilatation of the ascending aorta, which led to aortic valve replacement and its subsequent dysfunction because of thrombosis of the valve prosthesis. The frequency of detection of antiphospholipid antibodies (aPL), APS and thrombosis in AS is discussed. The role of tumor necrosis factor α (TNFα) inhibitors in the induction of aPL synthesis and the development of APS in patients with AS is considered either. Separately, we discussed the role of TNFα inhibitors, which are the main drugs in the treatment of ankylosing spondylitis, in the induction of aPL synthesis and the development of APS. Data on the occurrence of aPL, the reasons for the development of thrombosis in APS and the role of TNFα inhibitors remains incomplete. Perhaps the combination of APS and AS is an underestimated problem, and the information available in the literature does not reflect the real numbers. It is obvious that further research is needed to improve the treatment of patients with AS with thrombosis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антифосфолипидный синдром</kwd><kwd>анкилозирующий спондилит</kwd><kwd>аортит</kwd><kwd>антифосфолипидные антитела</kwd><kwd>тромбозы</kwd><kwd>ингибиторы фактора некроза опухоли α</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antiphospholipid syndrome</kwd><kwd>ankylosing spondylitis</kwd><kwd>antiphospholipid antibodies</kwd><kwd>thrombosis</kwd><kwd>tumor necrosis factor alpha inhibitors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71.</mixed-citation><mixed-citation xml:lang="en">Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.</mixed-citation><mixed-citation xml:lang="en">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Emmi G, Silvestri E, Squatrito D, et al. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal. 2014;2014:341342. doi: 10.1155/2014/341342. Epub 2014 Oct 14.</mixed-citation><mixed-citation xml:lang="en">Emmi G, Silvestri E, Squatrito D, et al. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal. 2014;2014:341342. doi: 10.1155/2014/341342. Epub 2014 Oct 14.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Эрдес ШФ, Бочкова АГ, Дубинина ТВ и др. Проект рабочей классификации анкилозирующего спондилита. Научно-практическая ревматология. 2013;51(6):604-8.</mixed-citation><mixed-citation xml:lang="en">Erdes ShF, Bochkova AG, Dubinina TV, et al. Draft working classification of ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya. 2013;51(6):604-8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Liao X and Shi G. Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies. Front Immunol. 2019 Jan 22;10:5. doi: 10.3389/fimmu.2019.00005. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Liu Y, Liao X and Shi G. Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies. Front Immunol. 2019 Jan 22;10:5. doi: 10.3389/fimmu.2019.00005. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Годзенко АА, Бочкова АГ, Мухортова ОВ и др. Аортит при анкилозирующем спондилите: возможности диагностики и лечения. Научно-практическая ревматология 2013;51(4):451-5.</mixed-citation><mixed-citation xml:lang="en">Godzenko AA, Bochkova AG, Mukhortova OV, et al. Aortitis in ankylosing spondylitis: diagnostic and treatment options. Nauchno-prakticheskaya revmatologiya 2013;51(4):451-5. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Годзенко АА, Бочкова АГ, Корсакова ЮО и др. Поражение сердца при анкилозирующем спондилите. Научно-практическая ревматология. 2009;47(4):4-10.</mixed-citation><mixed-citation xml:lang="en">Godzenko AA, Bochkova AG, Korsakova YuO, et al. Heart damage in ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya. 2009;47(4):4-10. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чельдиева ФА, Решетняк ТМ. Ревматоидный артрит: некоторые компоненты гемостаза и воспаление. Современная ревматология. 2019;13(3):87-94. doi: 10.14412/1996-7012-2019-3-87-94</mixed-citation><mixed-citation xml:lang="en">Chel'dieva FA, Reshetnyak TM. Rheumatoid arthritis: some components of hemostasis and inflammation. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(3):87-94. (In Russ.). doi: 10.14412/1996-7012-2019-3-87-94</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Juanola X, Mateo L, Domenech P, et al. Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. J Rheumatol. 1995 Oct;22(10):1891-3.</mixed-citation><mixed-citation xml:lang="en">Juanola X, Mateo L, Domenech P, et al. Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. J Rheumatol. 1995 Oct;22(10):1891-3.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Buchanan RR, Wardlaw JR, Riglar AG, et al. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol. 1989 Jun;16(6):757-61.</mixed-citation><mixed-citation xml:lang="en">Buchanan RR, Wardlaw JR, Riglar AG, et al. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol. 1989 Jun;16(6):757-61.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Niladri Usha, Kavyanjali Sharma, Shailja Singh, et al. Is Seronegative Spondyloarthritides (SSA) Truly Seronegative? IgGRheumatoid Factor, Anti-Nuclear Ab, and Anticardiolipin Ab can be Positive in SSA Also. J Immune Serum Biol. 2015;1(1):1-4.</mixed-citation><mixed-citation xml:lang="en">Niladri Usha, Kavyanjali Sharma, Shailja Singh, et al. Is Seronegative Spondyloarthritides (SSA) Truly Seronegative? IgGRheumatoid Factor, Anti-Nuclear Ab, and Anticardiolipin Ab can be Positive in SSA Also. J Immune Serum Biol. 2015;1(1):1-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chu de Reims. Ankylosing Spondylitis and Antiphospholipid Antibodies (ASAA). Clinical Trials. gov Identifier: NCT02809300.</mixed-citation><mixed-citation xml:lang="en">Chu de Reims. Ankylosing Spondylitis and Antiphospholipid Antibodies (ASAA). Clinical Trials. gov Identifier: NCT02809300.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tortosa C, Cabrera-Marante O, Serrano M, et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti І2 glycoprotein-I antibodies. PLoS One. 2017 Jul 20; 12(7):e0178889. doi: 10.1371/journal.pone.0178889. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">Tortosa C, Cabrera-Marante O, Serrano M, et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti І2 glycoprotein-I antibodies. PLoS One. 2017 Jul 20; 12(7):e0178889. doi: 10.1371/journal.pone.0178889. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Blanchard B, Lazareth I, Brossel C, et al. Lupus anticoagulant and leg ulcers associated with ankylosing spondylitis. J Rheumatol. 1991 Dec;18(12):1922-3.</mixed-citation><mixed-citation xml:lang="en">Blanchard B, Lazareth I, Brossel C, et al. Lupus anticoagulant and leg ulcers associated with ankylosing spondylitis. J Rheumatol. 1991 Dec;18(12):1922-3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ames PR, Lubrano E, Searpa R, et al. Lupus anticoagulant, ankylosing spondylitis and thrombosis. J Rheumatol. 1993 Sep; 20(9):1626-8.</mixed-citation><mixed-citation xml:lang="en">Ames PR, Lubrano E, Searpa R, et al. Lupus anticoagulant, ankylosing spondylitis and thrombosis. J Rheumatol. 1993 Sep; 20(9):1626-8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mateo L, Juanola X, Nolla JM, et al. Antiphospholipid syndrome in patients with ankylosing spondylitis. Presentation of 2 cases. Med Clin (Barc). 1992 Mar 14;98(10):381-3.</mixed-citation><mixed-citation xml:lang="en">Mateo L, Juanola X, Nolla JM, et al. Antiphospholipid syndrome in patients with ankylosing spondylitis. Presentation of 2 cases. Med Clin (Barc). 1992 Mar 14;98(10):381-3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z.</mixed-citation><mixed-citation xml:lang="en">Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Avina-Zubieta JA, Chan J, De Vera M, et al. Risk of venous thromboembolism in ankylosing spondylitis: a general populationbased study. Ann Rheum Dis. 2019 Apr;78(4): 480-5. doi: 10.1136/annrheumdis-2018-214388. Epub 2019 Feb 8.</mixed-citation><mixed-citation xml:lang="en">Avina-Zubieta JA, Chan J, De Vera M, et al. Risk of venous thromboembolism in ankylosing spondylitis: a general populationbased study. Ann Rheum Dis. 2019 Apr;78(4): 480-5. doi: 10.1136/annrheumdis-2018-214388. Epub 2019 Feb 8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez-Zamora P, de la Flor-Robledo M. Acute lung injury as a consequence of fresh frozen plasma administration in a patient with factor XII deficiency. Rev Esp Anestesiol Reanim. 2014 Oct;61(8):446-50. doi: 10.1016/j.redar.2013.09.012. Epub 2013 Nov 17.</mixed-citation><mixed-citation xml:lang="en">Sanchez-Zamora P, de la Flor-Robledo M. Acute lung injury as a consequence of fresh frozen plasma administration in a patient with factor XII deficiency. Rev Esp Anestesiol Reanim. 2014 Oct;61(8):446-50. doi: 10.1016/j.redar.2013.09.012. Epub 2013 Nov 17.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cornudella R, Puente F, Hortells JL, Gutierrez M. Moderate deficiency of Factor XII associated with postoperative deep venous thrombosis. Sangre (Barc). 1989 Apr; 34(2):144-146.</mixed-citation><mixed-citation xml:lang="en">Cornudella R, Puente F, Hortells JL, Gutierrez M. Moderate deficiency of Factor XII associated with postoperative deep venous thrombosis. Sangre (Barc). 1989 Apr; 34(2):144-146.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Becarevic M. Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. J Thromb Thrombolysis. 2017 Nov;44(4):565-570. doi: 10.1007/s11239-017-1571-4.</mixed-citation><mixed-citation xml:lang="en">Becarevic M. Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. J Thromb Thrombolysis. 2017 Nov;44(4):565-570. doi: 10.1007/s11239-017-1571-4.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72. doi: 10.1016/j.cytogfr.2014.07.016. Epub 2014 Aug 1.</mixed-citation><mixed-citation xml:lang="en">Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72. doi: 10.1016/j.cytogfr.2014.07.016. Epub 2014 Aug 1.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Alijotas-Reig J, Esteve-Valverde E, Llurba E, Gris JM. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. Semin Arthritis Rheum. 2019 Oct;49(2):314-8. doi: 10.1016/j.semarthrit.2019.02.006. Epub 2019 Feb 11.</mixed-citation><mixed-citation xml:lang="en">Alijotas-Reig J, Esteve-Valverde E, Llurba E, Gris JM. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. Semin Arthritis Rheum. 2019 Oct;49(2):314-8. doi: 10.1016/j.semarthrit.2019.02.006. Epub 2019 Feb 11.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Rep. 2010 Jan 15;4:12. doi: 10.1186/1752-1947-4-12.</mixed-citation><mixed-citation xml:lang="en">Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Rep. 2010 Jan 15;4:12. doi: 10.1186/1752-1947-4-12.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
